Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Hims & Hers Health, Inc.

Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...

Hims & Hers Health, a telehealth company, offers direct-to-patient platform to distribute prescription drugs and OTC medications. Read why I rate HIMS a sell.

Hers provides prescription medication and support for weight loss, hair growth, sexual health, and more. Learn more about this telehealth company.

Hims & Hers Health guided for second-quarter revenue of $530 million to $550 million versus estimates of $564.56 million. The company said it continues to expect full-year 2025 revenue in the ...

Hims & Hers Health also provided a longer-term outlook, laying out expectations for at least $6.5 billion in annual revenue for full-year 2030, and adjusted EBITDA of at least $1.3 billion.